ARMP
What one share of Armata Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
Armata Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.27 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.71 |
| Cash and investments | $0.64 |
| Book value | −$6.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$24.67 | $0.28 | −$11.06 | — | $5.90 |
| 2017 | — | −$2.18 | $0.01 | −$1.41 | — | $2.56 |
| 2018 | — | −$3.59 | $0.19 | −$2.47 | — | $1.52 |
| 2019 | — | −$2.55 | $0.03 | −$1.97 | — | $1.47 |
| 2020 | — | −$1.35 | $0.05 | −$1.16 | — | $1.01 |
| 2021 | — | −$0.96 | $0.05 | −$1.03 | — | $0.94 |
| 2022 | — | −$1.08 | $0.06 | −$1.01 | — | $1.00 |
| 2023 | — | −$1.91 | $0.23 | −$1.54 | — | −$0.89 |
| 2024 | — | −$0.89 | $0.03 | −$0.67 | — | −$1.33 |
| 2025 | — | −$4.80 | $0.01 | −$0.73 | — | −$6.00 |